In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $105.00. The company’s shares closed yesterday at $72.78.
According to TipRanks, Tenthoff is a 4-star analyst with an average return of 8.8% and a 41.52% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Crispr Therapeutics AG, and Arrowhead Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $84.10 average price target, a 15.55% upside from current levels. In a report released yesterday, JMP Securities also maintained a Buy rating on the stock with a $86.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $76.97 and a one-year low of $37.55. Currently, Crispr Therapeutics AG has an average volume of 2.81M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Crispr Therapeutics AG (CRSP) Company Description:
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
Read More on CRSP:
- Crispr Therapeutics Secures Funding Through Share Issuance
- Crispr Therapeutics’ Gene Therapy Wins EU Approval
- European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
- Is CRSP a Buy, Before Earnings?
- Crispr Therapeutics call volume above normal and directionally bullish
